Arrowhead Research Corporation develops novel drugs to treat
intractable diseases in the United States. The company’s principal
product candidates comprise ARC-520, an RNAi-based therapeutic that is
in Phase IIa clinical trial to treat chronic hepatitis B virus
infection; and ARC-AAT, a novel unlocked nucleobase analog containing
RNAi-based therapeutic for the treatment of liver disease associated
with alpha-1 antitrypsin deficiency. Its platform technology include
Dynamic Polyconjugate platform, an RNAi delivery system that addresses
multiple organ systems and cell types. The company is also involved in
the development of Adipotide, which is in phase I clinical trial for the
treatment of obesity and metabolic disorders; and CRLX-101 that is in
phase II clinical trial to treat various cancer types, including
relapsed renal cell carcinoma, relapsed ovarian cancer, and
non-metastatic rectal cancer. It has research collaboration and license
agreement with Shire AG to develop and commercialize targeted
peptide-drug conjugates.
Take a look at the 1-year chart of Arrowhead (NASDAQ: ARWR) with the added notations:
ARWR fell off a cliff in October of 2015, but the stock finally found
a bottom in December, eventually finding support at $6.00 (green). ARW
has hit that support level multiple times so far this year, and now that
the stock is testing that support level once again. Traders could
expect some sort of bounce, but if the $6.00 support were to break,
lower prices should follow.
The Tale of the Tape: ARWR has an important level of
support at $6.00. A trader could enter a long position at $6.00 with a
stop placed under the level. If the stock were to break below the
support a short position could be entered instead.
No comments:
Post a Comment